Poly(2-oxazoline) Micelles for Co-Delivery of Paclitaxel and Metronidazole Benzoate for Dual Chemotherapeutic and Antibacterial Targeting in the Tumor Microenvironment
Aug 2026· Biomedical microdevices· Vol 28· 0 citations· 44 references
Medicine
TL;DR
A poly(2-oxazoline) micelle (POx) platform co-encapsulating paclitaxel (PTX) and metronidazole benzoate (MB) to achieve concurrent delivery of anticancer and antibacterial agents is reported, highlighting the potential of POx micelles as a versatile platform for targeting both cancer cells and tumor-associated pathogens.
Abstract
Tumor-resident pathogenic bacteria can promote cancer progression and reduce chemotherapy efficacy, yet strategies to simultaneously target both tumor cells and intratumoral microbes remain limited. Here, we report a poly(2-oxazoline) micelle (POx) platform co-encapsulating paclitaxel (PTX) and metronidazole benzoate (MB) to achieve concurrent delivery of anticancer and antibacterial agents. The POx/PTX/MB micelles produced monodisperse populations with high drug loading efficiency and capacity and remained stable in physiological conditions. In vitro, the co-loaded formulation retained cytotoxic activity against two triple-negative breast cancer (TNBC) cell lines and bactericidal activity against Fusobacterium nucleatum. POx/PTX/MB micelles were well-tolerated at pharmacologically relevant doses in a murine model. This work provides a feasible strategy to integrate antimicrobial therapy with chemotherapy, highlighting the potential of POx micelles as a versatile platform for targeting both cancer cells and tumor-associated pathogens. These findings support further development of combination chemotherapeutic–antimicrobial strategies for tumors harboring pathogenic bacteria.
The management of colorectal cancer is constrained by a self-perpetuating vicious cycle, driven initially by gut microbiota dysbiosis that triggers chronic inflammation, which in turn promotes the establishment of an immunosuppressive tumor microenvironment and multidrug resistance. We engineered a glutathione (GSH)-re...
Yu Qiao, Shuai Yu, Chen Li et al.· Biomaterials Research· 0 citations
Platinum-based drugs are clinically vital for cancer treatment but suffer from off-target cytotoxicity and poor tumor penetration. To overcome these limitations, we designed a tumor-targeted Pt(IV) drug-bacteria conjugate (Pt-EcN-HER2). This conjugate exploits the inherent tumor tropism of probiotic bacterium Escherich...
He Meng, Jin-Hui Wang, Bing Shi et al.· Angewandte Chemie· 0 citations
Lung cancer remains the most commonly diagnosed malignancy and a leading cause of cancer-related mortality worldwide. Paclitaxel (PTX), a first-line chemotherapeutic agent for advanced non-small cell lung cancer (NSCLC), is frequently compromised by acquired drug resistance. Here, through network pharmacology analysis...
Ze-Jin Shen, Xu-Ran Kou, Ming-Yuan Wang et al.· Journal of Biomaterials Appl...· 0 citations
Background/Objectives: Cancer causes high premature death worldwide, with 35 million new cases expected by 2050. Multidrug resistance (MDR), driven by genetic and epigenetic changes, hampers chemotherapy. In this study, polymeric nanoparticles (NPs) were formulated with an organoselenium nucleoside analogue (AFAT-Se) t...
Bruna Fracari Do Nascimento, Bianca Costa Maia-do-Amaral, Taís Baldissera Pieta et al.· Future Pharmacology· 0 citations
A hypoxia-responsive theranostic mesoporous silica nanoparticles for the selective delivery of PTX and a coumarin fluorescent dye to hypoxic tumors selectively reduced the viability of A549 lung cancer cells under hypoxic conditions while exhibiting high biocompatibility with healthy THP-1 macrophages in normoxia.
Paula Rodrigo-Martínez, Lamiaa Mohamed Ahmed Ali, C. Coll et al.· International journal of pha...· 0 citations
TPGS–pyrimethamine micelles enhance cellular uptake and are associated with increased ROS generation, apoptosis, and cell-cycle alterations in MDA-MB-231 cells, together with tumour suppression in a murine lymphoma model, which support further preclinical investigation of TPGS-based pyrimethamine micelles as a potentia...
Indrajeet Yadav, Manisha Nidhar, Pavan Goud et al.· DARU Journal of Pharmaceutic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.